These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688 [TBL] [Abstract][Full Text] [Related]
7. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T; BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Moore KN; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; O'Cearbhaill RE; Guntupalli SR; Armstrong DK; Hagemann AR; Gray HJ; Duska LR; Mathews CA; Chen A; O'Malley D; Gordon S; Fracasso PM; Aghajanian C Gynecol Oncol; 2020 Jan; 156(1):13-22. PubMed ID: 31708167 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473 [TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Backes FJ; Wei L; Chen M; Hill K; Dzwigalski K; Poi M; Phelps M; Salani R; Copeland LJ; Fowler JM; Cohn DE; Bixel K; Cosgrove C; Hays J; O'Malley D Gynecol Oncol; 2021 Sep; 162(3):619-625. PubMed ID: 34272090 [TBL] [Abstract][Full Text] [Related]
11. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Richardson DL; Moore KN; Vergote I; Gilbert L; Martin LP; Mantia-Smaldone GM; Castro CM; Provencher D; Matulonis UA; Stec J; Wang Y; Method M; O'Malley DM Gynecol Oncol; 2024 Jun; 185():186-193. PubMed ID: 38447347 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113 [TBL] [Abstract][Full Text] [Related]
13. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ; Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365 [TBL] [Abstract][Full Text] [Related]
14. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190 [TBL] [Abstract][Full Text] [Related]
15. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial. Wu X; Liu J; An R; Yin R; Zhang Y; Zhou H; He A; Wang L; Zhang J; Liu Z; Duan W; Zhu J; Lou G; Chen G; Cheng Y; Xue F; Nick S; Wang H; Li D J Gynecol Oncol; 2024 Sep; 35(5):e99. PubMed ID: 38872480 [TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619 [TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Kelly MG; Mor G; Husband A; O'Malley DM; Baker L; Azodi M; Schwartz PE; Rutherford TJ Int J Gynecol Cancer; 2011 May; 21(4):633-9. PubMed ID: 21412168 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991 [TBL] [Abstract][Full Text] [Related]
19. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. González-Martín A; Pautier P; Mahner S; Rau J; Colombo N; Ottevanger P; Del Campo JM; Selle F; du Bois A; Gadducci A; García Y; Berton-Rigaud D; Marmé F; Ortega E; Martin N; Bastiere-Truchot L; Kiermaier A; Kurzeder C Int J Gynecol Cancer; 2016 Jun; 26(5):898-905. PubMed ID: 27206218 [TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Goff BA; Holmberg LA; Veljovich D; Kurland BF; Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]